Rare Benign Lesion of Peins

Status Completed

Clinical Trial Summary

PEKMB was first named and described by Lortat-Jacob & Civatte in 1961 and by Bart & Kopf later. This rare condition is mostly reported in elderly males. The keratotic scales is usually micaceous and resembles psoriasis. Most patients are above 50 years of age and are circumcised later in life, but also reported in younger age group. This mica like scales contains keratin which gets dissolved in 10% potassium hydroxide solution. Disease progression may lead to phimosis. Differential diagnosis of this disease entity include moniliasis, wart, psoriasis ,penile horn, circinate balanitis, erythroplasia of Queyrat, squamous cell epithelioma and verrucous carcinoma. It is primarily a benign entity, it is capable of invasiveness. Bart and Kopf considered it to be in intermediate stage between benign hyperplasia and squamous cell carcinoma. However, the histological spectrum can range from hypertrophic-hyperplastic penile dystrophy to verrucous carcinoma. Fibro sarcoma has been reported developing in a same patient. Etiology is unclear. Despite search for a viral agent, Human Papilloma Virus (HPV) has not been demonstrated and its role in pathogenesis or its transformation to verrucous carcinoma has been proved. The treatment of PEKMB should be conservative when there is no histological evidence of malignancy. All such patients should be followed up. Treatment choices include potent topical steroids, topical 5% 5-flurouracil cream1, 2, cryotherapy, radiotherapy and shaving biopsy plus electro coagulation. When frank malignancy is observed, excision with wide margin is the rule.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04725292
Study type	Observational
Source	Assiut University
Contact
Status	Completed
Phase
Start date	January 12, 2021
Completion date	January 12, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05038982` - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin	Phase 2
Completed	`NCT03563066` - Effect of Benralizumab in Atopic Dermatitis	Phase 2
Recruiting	`NCT04818138` - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort	N/A
Recruiting	`NCT05102396` - Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?	Phase 2
Completed	`NCT02916888` - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists	N/A
Completed	`NCT00772447` - China Registration Study in Patients With Skin Infections	Phase 3
Recruiting	`NCT01631617` - Effects of Treatments on Atopic Dermatitis	Phase 2
Active, not recruiting	`NCT04971200` - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo	Early Phase 1
Completed	`NCT04144491` - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda	N/A
Recruiting	`NCT04138342` - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer	Phase 1
Recruiting	`NCT06061471` - To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis	Phase 2
Terminated	`NCT04775316` - Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing
Recruiting	`NCT05765461` - Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
Withdrawn	`NCT04593914` - A Novel Skin Barrier Protectant for Acute Radiodermatitis	N/A
Completed	`NCT03720470` - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Phase 3
Recruiting	`NCT06092866` - Digital Versus Telephone Symptom Assessment and Triage in Primary Care	N/A
Recruiting	`NCT04901325` - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Phase 2
Recruiting	`NCT01917279` - Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC	Phase 3
Completed	`NCT01975038` - Adaption of the Skin Sun Sensitivity Scale	N/A
Recruiting	`NCT01427400` - The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction	Phase 4